(S)-2-(tert-butoxycarbonylamino)-4-methylsulfonyl-1-butanol | 168648-48-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: (S)-2-(tert-butoxycarbonylamino)-4-methylsulfonyl-1-butanol
• 英文别名: (S)-tert-butyl 1-hydroxy-4-(methylsulfonyl)butan-2-ylcarbamate；[S-[2-[(1,1-dimethylethoxy)carbonyl]amino]-4-methylsulfonyl]-butan-1-ol；tert-butyl N-[(2S)-1-hydroxy-4-methanesulfonylbutan-2-yl]carbamate；tert-butyl N-[(2S)-1-hydroxy-4-methylsulfonylbutan-2-yl]carbamate
• CAS: 168648-48-4
• 化学式: C₁₀H₂₁NO₅S
• 分子量: 267.346
• InChiKey: ABRBNBNYXZSVJU-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-2-(tert-butoxycarbonylamino)-4-methylsulfonyl-1-butanol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-(tert-butoxycarbonylamino)-4-(methanesulfonyl)butanal
  参考文献：
  名称：

  Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl

  摘要：

  A systematic study of anilines led to the discovery of a metabolically robust fluoroindoline replacement for the alkoxy aniline toxicophore in 1. Investigations of the PI pocket resulted in the discovery of a wide tolerance of functionality leading to the discovery of 11 as a potent and selective inhibitor of cathepsin S. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.056
• 作为产物：
  描述：

  N-叔丁氧羰基-L-蛋氨醇 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以94%的产率得到(S)-2-(tert-butoxycarbonylamino)-4-methylsulfonyl-1-butanol
  参考文献：
  名称：

  Copper (II) in organic synthesis. XI. Evaluation of the ligand architecture on the efficiency of a copper (II) catalyst for enantioselective Michael reactions

  摘要：

  Several bis-copper (II) complexes with chiral ligands derived from 2-substituted 2-(salicylideneamino) ethanols have been tested as catalysts of enantioselective Michael reactions. The degree of enantioselection is strongly affected by the architecture of the ligand. The best result (75% e.e.) was obtained for a ligand having a substituent potentially suitable to induce the formation of a bis-tetradentate copper (II) complex with a square pyramidal coordination.

  DOI：

  10.1016/0040-4020(95)00130-z

文献信息

• Imidazole-containing inhibitors of farnesyl protein transferase
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0675112A1

  公开（公告）日：1995-10-04

  Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formula their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein:    G is    G¹ is    G² is or -NR¹⁰-CH(Q¹)-;    J, K and L are each, independently, N, NR⁹, O, S or CR¹⁰ with the provisos that only one of the groups J, K and L can be O or S, and at least one of the groups J or L must be N, NR⁹, O or S to form a fused five-membered heteroring; the bond between J and K or K and L may also form one side of a phenyl ring fused to the fused five-membered heteroring;    Q is aryl;    Q¹, A¹ and A² are each, independently, H, alkyl, substituted alkyl, phenyl or substituted phenyl;    G³ is R¹¹, -C(O)OR¹¹, -C(O)NR¹¹R¹², 5-tetrazolyl, -C(O)N(R¹³)OR¹¹, -C(O)NHSO₂R¹⁴ or -CH₂OR¹¹;    G⁴ is attached at the 1, 2, 4 or 5 position and optionally substituted, at any of the available position or positions on the ring, with halo, alkyl or substituted alkyl having 1 to 20 carbon atoms, alkoxy, aryl, aralkyl, hydroxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, alkylthiono, alkylsulfonyl, sulfonamido, nitro, cyano, carboxy, carbamyl, N-hydroxycarbamyl, N-alkylcarbamyl, N-dialkylcarbamyl, alkoxycarbonyl, phenyl, substituted phenyl, or a combinaton of these groups;    Y and Z are each, independently, -CH₂- or -C(O)-;    R¹ - R¹⁴ are each, independently, H or alkyl having 1 to 20 carbon atoms;    R⁷, R⁸ and R¹⁴ may also be aryl or aralkyl, and R³, R⁹, R¹¹, R¹² and R¹³ may also be aralkyl;    m, n and p are each, independently, 0 or an integer from 1 to 2;    q is 0 or an integer from 1 to 4; and    the dotted line represents an optional double bond.

  抑制法尼醇转移酶是一种参与ras癌基因表达的酶，其受化合物的影响，其化合物包括其对映异构体、非对映异构体和药用可接受的盐、前药和溶剂化合物，其中： G为G¹为G²为或-NR¹⁰-CH(Q¹)-；J、K和L分别独立地为N、NR⁹、O、S或CR¹⁰，但有以下规定：J、K和L中只有一个可以是O或S，且J或L中至少有一个必须是N、NR⁹、O或S以形成融合的五元杂环；J和K之间的键或K和L之间的键也可以形成与融合的五元杂环融合的苯环的一侧；Q为芳基；Q¹、A¹和A²分别独立地为H、烷基、取代烷基、苯基或取代苯基；G³为R¹¹、-C(O)OR¹¹、-C(O)NR¹¹R¹²、5-四唑基、-C(O)N(R¹³)OR¹¹、-C(O)NHSO₂R¹⁴或-CH₂OR¹¹；G⁴附着在1、2、4或5位，并可选择地取代在环上的任何可用位置或位置，取代基为卤素、烷基或取代烷基（碳原子数为1至20）、烷氧基、芳基、芳基烷基、羟基、烷酰基、烷酰氧基、氨基、烷基氨基、二烷基氨基、烷酰氨基、硫醇基、烷基硫基、烷基硫酰基、磺酰胺基、硝基、氰基、羧基、氨基甲酰基、N-羟基氨基甲酰基、N-烷基氨基甲酰基、N-二烷基氨基甲酰基、烷氧基羰基、苯基、取代苯基或上述基团的组合；Y和Z分别独立为-CH₂-或-C(O)-；R¹-R¹⁴分别独立为H或烷基（碳原子数为1至20）；R⁷、R⁸和R¹⁴也可以是芳基或芳基烷基，R³、R⁹、R¹¹、R¹²和R¹³也可以是芳基烷基；m、n和p分别独立地为0或1至2的整数；q为0或1至4的整数；虚线表示可选的双键。
• Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto
  申请人：TEEGARDEN BRADLEY

  公开号：US20120270861A1

  公开（公告）日：2012-10-25

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及式(Ia)的某些化合物及其制药组合物，这些化合物调节5-HT2A 5-羟色胺受体的活性。这些化合物及其制药组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合征、躁狂障碍、器质性或非器质性精神病、精神病、急性精神分裂症、慢性精神分裂症、非特异性精神分裂症及相关疾病以及睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等方面的治疗方法。本发明还涉及与其他药物分别或同时给予的联合治疗5-HT2A 5-羟色胺受体相关疾病的方法。
• PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Teegarden Bradley

  公开号：US20140235622A1

  公开（公告）日：2014-08-21

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及公式（Ia）的某些化合物及其药物组合物，可调节5-HT2A 5-羟色胺受体的活性。这些化合物和药物组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、房颤、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合症、躁狂障碍、器质性或NOS精神病、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等治疗方法。本发明还涉及与其他药物代理分别或联合给药治疗5-HT2A 5-羟色胺受体相关疾病的方法。
• PRIMARY AMINES AND DERIVITVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US20170189381A1

  公开（公告）日：2017-07-06

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
• US8148417B2
  申请人：——

  公开号：US8148417B2

  公开（公告）日：2012-04-03